A randomised trial investigating the dose intensity of primary chemotherapy in patients with ovarian carcinoma: a comparison of chemotherapy given every four weeks with the same chemotherapy given at three week intervals.
Jayson, Gordon C
Ranson, Malcolm R
Prendiville, Joseph A
Collins, C D
Buckley, C H
Radford, John A
AffiliationCRC Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, UK.
MetadataShow full item record
AbstractBACKGROUND: The dose intensity of chemotherapy for patients with ovarian carcinoma remains a controversial issue. Few randomised trials have been conducted examining dose intensity using the same total dose of chemotherapy. This study was designed to investigate two schedules of chemotherapy using standard and higher dose intensity with both groups receiving the same total dose. PATIENTS AND METHODS: Patients with FIGO stage IC, II, III and IV epithelial ovarian carcinoma were randomised to receive cycles of cyclophosphamide (600 mg/m2) and carboplatin (300 mg/m2) alternating with doxorubicin (50 mg/ m2) and ifosfamide (5 g/m2) at either four-weekly (n = 47) or three-weekly (n = 97) intervals (1:2 randomisation). At randomisation patients were stratified according to histological grade and amount of post operative residual tumour (greater or less than 2 cm). The two arms of the study were well balanced in terms of the major prognostic features. RESULTS: There was no difference in either progression free survival or overall survival between the two arms. The median overall survival was 730 days for the three-weekly treatment and 740 days in the four-weekly arm (progression-free survival was 500 days and 483 days, respectively). The combined overall response rate (complete and partial response) in the 114 assessable patients was 65.7% (66.7% for the three-weekly treatment and 64% for the four-weekly treatment). These differences were not statistically different. CONCLUSIONS: A modest increase in the dose intensity of chemotherapy (1:3 fold) failed to improve the response rate, progression-free survival and overall survival in patients with ovarian carcinoma.
CitationA randomised trial investigating the dose intensity of primary chemotherapy in patients with ovarian carcinoma: a comparison of chemotherapy given every four weeks with the same chemotherapy given at three week intervals. 1996, 7 (7):705-11 Ann. Oncol.
JournalAnnals of Oncology
- Mature results of a prospective randomized trial comparing a three-weekly with an accelerated weekly schedule of cisplatin in advanced ovarian carcinoma.
- Authors: Cocconi G, Bella M, Lottici R, Leonardi F, Ceci G, Passalacqua R, Di Blasio B, Bordi C, Biscottini B, Melpignano M, De Biasi D, Finardi C, Bacchi M
- Issue date: 1999 Dec
- A randomised dose intensity study in ovarian carcinoma comparing chemotherapy given at four week intervals for six cycles with half dose chemotherapy given for twelve cycles.
- Authors: Murphy D, Crowther D, Renninson J, Prendiville J, Ranson M, Lind M, Patel U, Dougal M, Buckley CH, Tindall VR
- Issue date: 1993 May
- Long-term results in patients with advanced epithelial ovarian carcinoma treated with a combination of cisplatin, doxorubicin, and cyclophosphamide.
- Authors: Colozza M, Mosconi AM, Gori S, Belsanti V, Basurto C, De Angelis V, Giansanti M, Tonato M
- Issue date: 1997 Oct
- Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
- Authors: Pignata S, Scambia G, Katsaros D, Gallo C, Pujade-Lauraine E, De Placido S, Bologna A, Weber B, Raspagliesi F, Panici PB, Cormio G, Sorio R, Cavazzini MG, Ferrandina G, Breda E, Murgia V, Sacco C, Cinieri S, Salutari V, Ricci C, Pisano C, Greggi S, Lauria R, Lorusso D, Marchetti C, Selvaggi L, Signoriello S, Piccirillo MC, Di Maio M, Perrone F, Multicentre Italian Trials in Ovarian cancer (MITO-7)., Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens et du sein (GINECO)., Mario Negri Gynecologic Oncology (MaNGO)., European Network of Gynaecological Oncological Trial Groups (ENGOT-OV-10)., Gynecologic Cancer InterGroup (GCIG) Investigators.
- Issue date: 2014 Apr
- ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
- Authors: Harper P
- Issue date: 1997 Oct